Salix's HIV-related drug gets priority-review status from FDA

02/7/2012 | Reuters

Salix Pharmaceuticals obtained FDA priority-review designation for crofelemer, a drug aimed at treating HIV-related diarrhea. An FDA decision is expected by June 5.

View Full Article in:

Reuters

Published in Brief: